Is This the Right Time to Add Resmed Stock to Your Portfolio?

Key Takeaways Resmed is benefiting from strong global demand for AirSense 10 and 11, driving higher device sales growth.RMD reported 10% sales growth across regions in Q1 FY26, supported by expansion in key international markets. Resmed ended Q1 FY26 with $1.38B in cash, low debt levels and a total debt-to-capital ratio of 6.3%. Resmed Inc. (RMD) continues to see strong demand for its market-leading AirSense 10 and AirSense 11 sleep devices. Expansion into international markets appears highly promising, sup ...